Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModraDoc006/r phase I safety, feasibility and pharmacokinetic study in metastatic castration-resistant prostate cancer
NL-OMON47810Phase 1Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ModraDoc006 and ritonavir in prostate cancer (PCa), sponsored by Modra Pharmaceuticals. Primary endpoint: Recommended dose / maximum tolerated dose. Started May 2017; status: completed.
02
Drugs
ModraDoc006ritonavir
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON47810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47810.